Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US

Launched in the US last October, the drug is expected to account for 2% of the country's neutropenia treatment market in 2023

Rolvedon, a neutropenia agent developed by Hanmi Pharmaceutical
Rolvedon, a neutropenia agent developed by Hanmi Pharmaceutical
Jae-Young Han 1
2023-02-02 00:35:30 jyhan@hankyung.com
Bio & Pharma

South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million in net sales in the US for the fourth quarter of 2022.

Spectrum Pharmaceuticals, Hanmi’s sales partner in the US, announced the figure based on preliminary unaudited financial results on Wednesday. The US drugmaker will announce detailed financial updates of the 2022 earnings in March. 

Rolvedon, called Rolontis in Korea, was launched in the US last October after it earned a marketing license from the Food and Drug Administration (FDA) in the same year. It is the first new oncology-targeting drug to be developed by a Korean pharmaceutical company and to receive FDA marketing approval.  

The neutropenia treatment decreases the incidence of infection in adult patients, who have non-myeloid malignancies and receive myelosuppressive anti-cancer drugs.

Rolvedon is expected to post about $60 million in revenue in the US market this year, accounting for 2% of neutropenia treatment in the country.

The drug achieved a meaningful result during the last quarter in the US neutropenia drug market, where Amgen Inc. is a strong player with Neulasta (pegfilgrastim) and Neupogen (filgrastim), said a Hanmi official. 

The Korean biotech will speed up the development of its other new drug candidates by using Lapscovery, its in-house technology that prolongs the residence time of a biologic and minimizes the frequency of treatment, the official said. 

Write to Jae-Young Han at jyhan@hankyung.com

Jihyun Kim edited this article. 
#Hanmi Pharmaceutical #neutropenia drug #Korean drugmaker #Korean biotech #Spectrum Pharmaceuticals #US FDA #Rolvedon neutropenia #Amgen Neulasta #Amgen Neupogen

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

An aerial view of Hanmi Pharmaceutical's headquarters  Hanmi Pharmaceutical Co. announced Friday that California-based Spectrum Pharmaceuticals Inc. received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA), which will delay a new drug’s release date.&n

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Rolontis, a neutropenia agent, will be sold in the US under the Rolvedon brand South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has obtained marketing approval from the US Food and Drug Administration.T

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

Rolontis, a neutropenia agent developed by Hanmi Pharmaceutical The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authorization of the white blood cell disease treatment.The FDA will complete its review of

Hanmi stands out with own drugs as Korean rivals sell imports

Hanmi stands out with own drugs as Korean rivals sell imports

Hanmi Pharmaceutical’s R&D staff in medication research (Courtesy of Hanmi) South Korea’s Hanmi Pharmaceutical Co. generated sales of more than 1 trillion won ($812.3 million) from its own medicines last year on strong demand for its blockbuster high blood pressure drug Amosarta
(* comment hide *}